国产精品视频一区二区三区四,亚洲av美洲av综合av,99国内精品久久久久久久,欧美电影一区二区三区电影

您好, 歡迎來到化工儀器網

| 注冊| 產品展廳| 收藏該商鋪

13611715263

products

目錄:MedChemExpress LLC>>生化試劑>> Obinutuzumab | MCE

Obinutuzumab | MCE
  • Obinutuzumab | MCE
參考價 8100
具體成交價以合同協(xié)議為準
參考價 8100
具體成交價以合同協(xié)議為準
  • 品牌 MedChemExpress (MCE)
  • 型號
  • 廠商性質 生產商
  • 所在地 國外
屬性

$NV_PropertyInfoName.SubString(0,25)

>

更新時間:2023-06-08 11:36:46瀏覽次數(shù):177評價

聯(lián)系我們時請說明是化工儀器網上看到的信息,謝謝!

同類優(yōu)質產品

更多產品
CAS 949142-50-1 純度 ≥99.4%
分子量 146298.97 供貨周期 現(xiàn)貨
規(guī)格 5 mg 貨號 HY-P9910
應用領域 醫(yī)療衛(wèi)生,化工,生物產業(yè),制藥/生物制藥
Obinutuzumab | MCEObinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。

Obinutuzumab

CAS No. : 949142-50-1

產品活性:Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

研究領域:Immunology/Inflammation

作用靶點:CD20

In Vitro: Obinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab

In Vivo: Obinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies.

相關產品:Plamotamab  |  Glofitamab  |  Divozilimab  |  Mosunetuzumab  |  Ofatumumab  |  Ublituximab  |  Ripertamab  |  Blontuvetmab  |  Imvotamab  |  Rituximab (anti-CD20)  |  Zuberitamab  |  Odronextamab  |  Tositumomab  |  Ocaratuzumab

熱門產品線:重組蛋白  |  化合物庫  |  天然產物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質小分子活性化合物;
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
•   產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發(fā)、生命科學等科研項目;
•   提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業(yè)技術服務;
•   設有專業(yè)的實驗中心和嚴格的質控、驗證體系;
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
•   產品的生物活性多經各國客戶實驗驗證;
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
•   專業(yè)團隊跟蹤新的制藥及生命科學研究進展,為您提供*新的活性化合物;
•   與世界各大制藥公司及*科研機構建立了長期的合作。

類藥多樣性化合物庫
顧客使用MCE產品發(fā)表的科研文獻
一站式藥篩新體驗
MCE 您身邊的生物活性分子大師 | 抑制劑、激動劑、化合物庫
重組蛋白 | 高純度、高穩(wěn)定性
磁珠

會員登錄

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

您的留言已提交成功!我們將在第一時間回復您~
在線留言

會員登錄

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:
熱線電話 在線詢價
鸡东县| 海口市| 远安县| 武邑县| 河津市| 桐梓县| 大关县| 米泉市| 育儿| 大埔区| 汉寿县| 陆河县| 青州市| 宣化县| 合水县| 淮安市| 梅州市| 朝阳县| 栾川县| 海门市| 五莲县| 广灵县| 静海县| 张家口市| 赤峰市| 额尔古纳市| 德格县| 永德县| 阿坝县| 广河县| 平江县| 永安市| 青河县| 称多县| 临澧县| 喀喇| 平江县| 海淀区| 谷城县| 宁河县| 鱼台县|